- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01778205
The Reus-Tarragona Birth Cohort Study of Early Development and Ageing.
September 16, 2021 updated by: Dr. Michelle Murphy, Institut Investigacio Sanitaria Pere Virgili
Phase 1 Study of the Effect of Maternal Nutritional Status on Placental Vascular Function, Fetal Growth and Intrauterine Growth Retardation.
The recent fall in birth and death rates has led to demographic changes such as low fertility and high life expectancy .
The WHO reports the median age of the European population to be the highest in the world and predicts that the proportion of over-60s in will increase from 14% in 2010 to 25% in 2050.
There is wide variability in the quality of health and well-being in the ageing population.
Longevity with a good quality of life is a consequence of the combination of an individual's genes, nutrition, environment, lifestyle and medical interventions.
There is increasing evidence that research into healthy ageing needs to start with early life data to capture all traits and exposures experienced by an individual throughout life.
Epigenetic imprinting occurs both in utero and during early postnatal development.
Maternal environmental exposures, including nutritional status, may have a permanent effect on the developing foetus by influencing epigenetic profiles and leading to life-long genome adaptation.
Numerous reports show that restricted intra-uterine growth due to poor maternal nutrition during pregnancy increases risk in the offspring of developing mental disorders, metabolic syndrome, cardiovascular disease or stroke in later life.
To understand the basic mechanisms and interactions through which the ageing phenotype develops, systems involved in key processes of early development must be considered as well as those crucial to health in older persons.
The Reus and Tarragona Birth Cohort is a longitudinal study.
In the first phase, blood is collected from pregnant women at <12, 15, 24-27 and 34 gestational weeks (GW) and at labor and from the cord.
Detailed lifestyle, habits and supplement use data are collected at 20 and 32 gestational weeks and on nutritional habits at <12GW and at birth.
Placental vascular function is assessed at 20 and 32 GW by analysis of Doppler waveforms of the uterine arteries.
Data on pregnancy evolution and outcome are also recorded.
The first phase investigates the association between gene-environment (nutrient and lifestyle habits) interactions and fetal growth and pregnancy outcome.
The second phase of the study follows up the children at 7.5 years of age.
Growth, exercise and nutritional habits as well as environment and cognitive development are assessed.
The aims are to investigate the association between gene-environment interactions associated with healthy development from early pregnancy until 7.5 years of age.
Study Overview
Study Type
Observational
Enrollment (Actual)
831
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tarragona, Spain, 43005
- Hospital de Tarragona Joan XXIII
-
-
Tarragona
-
Reus, Tarragona, Spain, 43201
- Hospital Universitari Sant Joan de Reus
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
Women less than 12 weeks pregnant at their first pre-natal check up are recruited from the URV University Hospitals: Sant Joan (Reus) and Joan XXIII (Tarragona)
Description
Inclusion Criteria:
- <12 weeks pregnant at first prenatal check up
Exclusion Criteria:
- Illnesses / interventions affecting nutritional status, major recent surgery in the previous 6 months, multiple pregnancies
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Pregnant women
Pregnant women with confirmed viable fetus at first prenatal check-up at <12 gestational weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Birth weight
Time Frame: At birth
|
At birth
|
Doppler waveforms of uterine arteries
Time Frame: 20 gestational weeks
|
20 gestational weeks
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
1-C metabolites
Time Frame: <12, 15, 24-27, 34 gestational weeks, at labor, in the cord
|
<12, 15, 24-27, 34 gestational weeks, at labor, in the cord
|
Intrauterine growth retardation
Time Frame: At birth
|
At birth
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Michelle M Murphy, PhD, Universitat Rovira i Virgili
- Study Director: Pere Cavallé-Busquets, MD, PHD, Hospital Universitari Sant Joan de Reus
- Study Chair: Joan D Fernandez-Ballart, PhD, Universitat Rovira i Virgili
- Study Director: Mónica Ballesteros, MD, PHD, Hospital de Tarragona Joan XXIII
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Colomina JM, Cavalle-Busquets P, Fernandez-Roig S, Sole-Navais P, Fernandez-Ballart JD, Ballesteros M, Ueland PM, Meyer K, Murphy MM. Maternal Folate Status and the BHMT c.716G>A Polymorphism Affect the Betaine Dimethylglycine Pathway during Pregnancy. Nutrients. 2016 Oct 9;8(10):621. doi: 10.3390/nu8100621.
- Sole-Navais P, Salat-Batlle J, Cavalle-Busquets P, Fernandez-Ballart J, Ueland PM, Ballesteros M, Ornosa-Martin G, Ingles-Puig M, Colomina JM, Murphy MM. Early pregnancy folate-cobalamin interactions and their effects on cobalamin status and hematologic variables throughout pregnancy. Am J Clin Nutr. 2018 Feb 1;107(2):173-182. doi: 10.1093/ajcn/nqx041.
- Roige-Castellvi J, Murphy M, Hernandez-Martinez C, Sole-Navais P, Cavalle-Busquets P, Fernandez-Ballart J, Ballesteros M, Canals J. The effect of prenatal smoke exposure on child neuropsychological function: a prospective mother-child cohort study. J Reprod Infant Psychol. 2020 Feb;38(1):25-37. doi: 10.1080/02646838.2019.1580350. Epub 2019 Feb 19.
- Cavalle-Busquets P, Ingles-Puig M, Fernandez-Ballart JD, Haro-Barcelo J, Rojas-Gomez A, Ramos-Rodriguez C, Ballesteros M, Meyer K, Ueland PM, Murphy MM. Moderately elevated first trimester fasting plasma total homocysteine is associated with increased probability of miscarriage. The Reus-Tarragona Birth Cohort Study. Biochimie. 2020 Jun;173:62-67. doi: 10.1016/j.biochi.2020.01.008. Epub 2020 Jan 18.
- Fernandez-Roig S, Cavalle-Busquets P, Fernandez-Ballart JD, Ballesteros M, Berrocal-Zaragoza MI, Salat-Batlle J, Ueland PM, Murphy MM. Low folate status enhances pregnancy changes in plasma betaine and dimethylglycine concentrations and the association between betaine and homocysteine. Am J Clin Nutr. 2013 Jun;97(6):1252-9. doi: 10.3945/ajcn.112.054189. Epub 2013 Apr 17.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2005
Primary Completion (Actual)
September 14, 2020
Study Completion (Actual)
September 14, 2020
Study Registration Dates
First Submitted
January 25, 2013
First Submitted That Met QC Criteria
January 25, 2013
First Posted (Estimate)
January 29, 2013
Study Record Updates
Last Update Posted (Actual)
September 23, 2021
Last Update Submitted That Met QC Criteria
September 16, 2021
Last Verified
September 1, 2021
More Information
Terms related to this study
Other Study ID Numbers
- IISPV_Murphy1
- SPAIN MICINN (Other Grant/Funding Number: Ministerio de Ciéncia y Innovación SAF2005/05096)
- SPAIN ISCIII (Other Grant/Funding Number: Instituto de Salud Carlos III PI19/00844)
- SPAIN URV (Other Grant/Funding Number: Universitat Rovira i Virgili)
- SPAIN AEI (Other Grant/Funding Number: Agencia Estatal Investigacion PCI2018-093098)
- Horizon 2020 (Other Grant/Funding Number: JPI ERA-HDHL Nutrition & The Epigenome)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intrauterine Development
-
Assiut UniversityCompletedIntrauterine DeviceEgypt
-
Cairo UniversityCompleted
-
Centre Hospitalier Universitaire de Saint EtienneSAINBIOSECompleted
-
Helsinki University Central HospitalCompletedIntrauterine ContraceptionFinland
-
Washington University School of MedicineCompletedIntrauterine ResuscitationUnited States
-
Kanuni Sultan Suleyman Training and Research HospitalCompletedIntrauterine DeviceTurkey
-
Instituto Valenciano de Infertilidad, IVI VALENCIACompleted
-
noha mohamed elzaydyUnknown
-
Assiut UniversityCompleted
-
Cairo UniversityCompletedIntrauterine DeviceEgypt
Clinical Trials on Observational
-
University of MinnesotaAgency for Healthcare Research and Quality (AHRQ)RecruitingTraumatic Brain Injury | Venous ThromboembolismUnited States
-
American Gastroenterological AssociationUniversity of Pennsylvania; University of California, San Diego; University of... and other collaboratorsRecruitingClostridium Difficile Infection | Gut Microbiome | Fecal Microbiota TransplantationUnited States, Canada
-
St. Louis UniversityActive, not recruitingVertebral Artery StenosisUnited States
-
Massachusetts General HospitalRecruiting
-
Taysha Gene Therapies, Inc.Withdrawn
-
University Hospital, AntwerpUniversiteit AntwerpenUnknownType 1 Diabetes | Diastolic Dysfunction | Coronary Artery CalcificationsBelgium
-
AstraZenecaRecruitingNon-Small Cell Lung CancerUnited States
-
University of ManitobaCompletedObesity | Pregnancy | Cesarean SectionCanada
-
University Hospital, Basel, SwitzerlandCompletedPostoperative Complications | Intraoperative Complications | Patient Safety | Risk ManagementNew Zealand, Switzerland, United States, Netherlands, Spain, Austria, Turkey, United Kingdom, Australia, Greece, Ireland, Italy
-
University of Castilla-La ManchaRecruitingKnee OsteoarthritisSpain